Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) CFO Sean F. Moran purchased 2,500 shares of the company’s stock in a transaction on Friday, August 11th. The shares were purchased at an average cost of $5.91 per share, for a total transaction of $14,775.00. Following the completion of the transaction, the chief financial officer now directly owns 339,410 shares of the company’s stock, valued at approximately $2,005,913.10. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ CRBP) opened at 6.3992 on Monday. The company’s market capitalization is $321.37 million. The stock has a 50 day moving average of $6.27 and a 200 day moving average of $7.09. Corbus Pharmaceuticals Holdings, Inc. has a 12 month low of $2.95 and a 12 month high of $10.78.

Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) last released its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.15) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.19) by $0.04. The company had revenue of $0.35 million for the quarter, compared to analysts’ expectations of $0.50 million. Corbus Pharmaceuticals Holdings had a negative return on equity of 107.10% and a negative net margin of 1,001.77%. Equities analysts anticipate that Corbus Pharmaceuticals Holdings, Inc. will post ($0.73) EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Corbus Pharmaceuticals Holdings, Inc. (CRBP) CFO Buys $14,775.00 in Stock” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece on another website, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be accessed at https://www.thecerbatgem.com/2017/08/14/corbus-pharmaceuticals-holdings-inc-crbp-cfo-buys-14775-00-in-stock.html.

Several analysts have issued reports on CRBP shares. Noble Financial reaffirmed a “buy” rating on shares of Corbus Pharmaceuticals Holdings in a research report on Saturday, May 6th. Cantor Fitzgerald set a $24.00 price target on shares of Corbus Pharmaceuticals Holdings and gave the stock a “buy” rating in a research report on Tuesday, May 9th. Finally, BidaskClub raised shares of Corbus Pharmaceuticals Holdings from a “sell” rating to a “hold” rating in a research report on Saturday, July 8th. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $20.50.

Several large investors have recently added to or reduced their stakes in the company. Evanson Asset Management LLC boosted its stake in Corbus Pharmaceuticals Holdings by 1.5% in the second quarter. Evanson Asset Management LLC now owns 20,660 shares of the biopharmaceutical company’s stock worth $130,000 after buying an additional 300 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in Corbus Pharmaceuticals Holdings by 7.7% in the first quarter. Bank of New York Mellon Corp now owns 21,102 shares of the biopharmaceutical company’s stock worth $174,000 after buying an additional 1,511 shares during the last quarter. Creative Planning boosted its stake in Corbus Pharmaceuticals Holdings by 2.4% in the first quarter. Creative Planning now owns 166,950 shares of the biopharmaceutical company’s stock worth $1,377,000 after buying an additional 3,983 shares during the last quarter. IPG Investment Advisors LLC acquired a new stake in Corbus Pharmaceuticals Holdings during the first quarter worth approximately $109,000. Finally, Quantbot Technologies LP acquired a new stake in Corbus Pharmaceuticals Holdings during the first quarter worth approximately $114,000. Institutional investors own 28.63% of the company’s stock.

Corbus Pharmaceuticals Holdings Company Profile

Corbus Pharmaceuticals Holdings, Inc is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases. The Company operates through developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases segment.

Insider Buying and Selling by Quarter for Corbus Pharmaceuticals Holdings (NASDAQ:CRBP)

Receive News & Stock Ratings for Corbus Pharmaceuticals Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals Holdings Inc. and related stocks with our FREE daily email newsletter.